戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sicular monoamine transport (VMAT) inhibitor tetrabenazine.
2 but was restored by treating the slices with tetrabenazine.
3 with d-methamphetamine, methylphenidate, and tetrabenazine.
4 nt with methamphetamine, methylphenidate, or tetrabenazine.
5  blocked by 1 microM reserpine and 10 microM tetrabenazine.
6 e neurotransmitters as well as the inhibitor tetrabenazine.
7 rotonin and histamine and the sensitivity to tetrabenazine.
8 ting the heterogeneous synthesis reaction of tetrabenazine.
9 R was blocked by 100 nM reserpine, 10 microM tetrabenazine, 1 mM serotonin, and 10 mM (-)-norepinephr
10 [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine ([125I]TBZ-AIPP).
11 2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6
12                                              Tetrabenazine, a monoamine depleter and dopamine recepto
13                               In addition to tetrabenazine, a monoamine-depleting drug, new formulati
14            All 19 patients continued to take tetrabenazine after the study.
15 inically relevant dopamine pathway inhibitor tetrabenazine alleviated the motor deficits and reduced
16   The pharmacologic inhibitors carbidopa and tetrabenazine also revealed differential effects between
17 ater (10:1) gave direct cyclization to (+/-)-tetrabenazine and occurred more rapidly.
18                 Drug therapy with benzhexol, tetrabenazine and pimozide or haloperidol may be benefic
19           Furthermore, transient exposure to tetrabenazine and reserpine, but not methyl reserpate an
20 s, we demonstrated that the VMAT2 inhibitors tetrabenazine and Ro 4-1284 inhibit P-GP and that the P-
21 tion K446Q reduced the affinity of VMAT2 for tetrabenazine and serotonin but not histamine, whereas F
22 enuated by inhibitors of VMAT (reserpine and tetrabenazine) and DAT (GBR12909 and rimcazole).
23 lowing 15-min incubations with reserpine and tetrabenazine, as evidenced by a decrease in exocytotic
24 cellular studies revealed that reserpine and tetrabenazine at concentrations near their K(i) values n
25 , demonstrating involvement of TM 10-12 in a tetrabenazine binding domain.
26 ffinity than the endo,endo analogue 3 at the tetrabenazine binding site on VMAT2, indicating that the
27 demonstrating that Cys(439) is either at the tetrabenazine binding site, or conformationally linked t
28  binding site, or conformationally linked to tetrabenazine binding.
29 binds the cytoplasm-facing conformation, and tetrabenazine binds the lumen-facing conformation.
30 rt than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2.
31                                              Tetrabenazine binds VMAT2 in a lumen-facing conformation
32  and histamine as well as the sensitivity to tetrabenazine but only in the context of more C-terminal
33                A behaviorally active dose of tetrabenazine decreased extracellular DA in nucleus accu
34                    VMAT2 inhibitors, such as tetrabenazine, deutetrabenazine, and valbenazine, show t
35 e rated after a mean of 20.3 weeks at a mean tetrabenazine dose of 57.9 mg/day.
36  complex with spermine, spermidine, H(+), or tetrabenazine, elucidating discrete lumen-facing states
37                            Citing the use of tetrabenazine for chorea in Huntington disease, adrenoco
38               The authors studied the use of tetrabenazine for tardive dyskinesia.
39 ol/g tissue) with a pharmacological profile (tetrabenazine > or = iodovinyltetrabenazine > ketanserin
40 erpine and one iodophenylazide derivative of tetrabenazine have been synthesized and characterized as
41 ognition of the ring nitrogen that occurs in tetrabenazine, histamine, and serotonin but not dopamine
42 nd Asp-461 with Asn reduced the affinity for tetrabenazine, histamine, and serotonin.
43 he higher affinity interaction of VMAT2 with tetrabenazine, histamine, and serotonin.
44 onalize how the antidopaminergic therapeutic tetrabenazine impedes vesicular transport of polyamines.
45 n addition, JJC8-089 reversed the effects of tetrabenazine in female rats.
46 -effort bias induced by the VMAT-2 inhibitor tetrabenazine, increasing selection of high-effort fixed
47 nic amine uptake, and in vivo by reversal of tetrabenazine-induced ptosis.
48                                              Tetrabenazine is a high-affinity inhibitor of the vesicu
49                                              Tetrabenazine is efficacious for chorea control; however
50  using pharmacological agents, bupropion and tetrabenazine, known to induce positive and negative CJB
51                               The effects of tetrabenazine on effort-related choice were reversed by
52  (one); discontinuation of lithium (one) and tetrabenazine (one); and the introduction of clonazepam
53 that antagonists of dopamine pathway such as tetrabenazine or dopamine receptor blockers may have a t
54                 One patient did not tolerate tetrabenazine owing to sedation.
55        Drug therapy used included benzhexol, tetrabenazine, pimozide, baclofen, chlorpromazine, halop
56 tension, and by the noncompetitive inhibitor tetrabenazine, presently in use for symptomatic treatmen
57      Additions of organometallic reagents to tetrabenazine produced 2-methyl, 2-ethyl, 2-n-propyl, 2-
58                                              Tetrabenazine produces depressive symptoms in humans and
59  Supporting a direct effect, the position of tetrabenazine-protectable Cys 439 is consistent with pre
60 esicles expressing VMAT2 show reserpine- and tetrabenazine-protectable photolabeling by [125I]IAmF.
61  the active metabolites of the prior, stable tetrabenazine regimen.
62 we now show that the sensitivity of VMAT2 to tetrabenazine requires Ala-315, and this interaction occ
63 ly unrelated drugs, including bromocriptine, tetrabenazine, rosiglitazone, nebivolol, sorafenib, cabo
64 uces serotonin but not histamine affinity or tetrabenazine sensitivity in the context of more N-termi
65 tonin affinity but not histamine affinity or tetrabenazine sensitivity, and whereas the region from T
66 ty and perhaps histamine recognition but not tetrabenazine sensitivity, providing more evidence for s
67 a partial increase in substrate affinity and tetrabenazine sensitivity.
68                                              Tetrabenazine shifted response choice in rats, producing
69 combined insights enable the optimization of tetrabenazine synthesis in terms of reaction time, bypro
70        The enantioselective synthesis of (+)-tetrabenazine (TBZ) and (+)-dihydrotetrabenazine (DTBZ),
71                                              Tetrabenazine (TBZ) is a non-competitive inhibitor of VM
72         Our results show that ketanserin and tetrabenazine (TBZ) strikingly abolished the aggressive
73 cular monoamine transport (VMAT-2) inhibitor tetrabenazine (TBZ) were investigated.
74 urified rVMAT2 were protectable by 10 microM tetrabenazine (TBZ), 10 microM 7-aminoketanserin, and 1
75  (cryo-EM) structure of VMAT2 complexed with tetrabenazine (TBZ), a non-competitive inhibitor used in
76 oved drug for the treatment of chorea in HD, tetrabenazine (TBZ).
77  and 2-N-[(3'-iodo-4'-azidophenyl)-propionyl]tetrabenazine (TBZ-AIPP).
78 ll as a greater sensitivity to the inhibitor tetrabenazine than the nonneuronal VMAT1.
79 on and the recognition of both histamine and tetrabenazine that may account for the observed differen
80 nd Australia who were taking stable doses of tetrabenazine that provided a therapeutic benefit were s
81 er VMAT2 in complex with the antichorea drug tetrabenazine, the antihypertensive drug reserpine or th
82  interactions with serotonin, histamine, and tetrabenazine, the region of VMAT2 from TMD3 through TMD
83 ng the VMAT2-specific ligands ketanserin and tetrabenazine, this study describes the synthesis and ch
84  and explore the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chore
85 ncreased stereotypies that were decreased by tetrabenazine treatment.
86 3.7 months) were videotaped before and after tetrabenazine treatment.
87                                        (+/-)-Tetrabenazine was synthesized in six steps from commerci
88                                              Tetrabenazine was well tolerated and resulted in signifi
89 ich blocks VMAT1 and VMAT2, but resistant to tetrabenazine, which is a selective inhibitor of VMAT2.
90           These experiments demonstrate that tetrabenazine, which is used in animal models to produce